Could a poop pill protect the liver? trial tests fecal transplants against cirrhosis complications
NCT ID NCT06533852
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether fecal microbiota transplantation (FMT) — capsules containing processed stool from healthy donors — can slow the progression of decompensated cirrhosis, a severe form of liver disease. About 190 adults with advanced cirrhosis will receive either FMT or a placebo at the start and again after three months. Researchers will track how long it takes for serious complications like kidney injury, internal bleeding, or infections to occur, and whether the treatment improves survival without a liver transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fecal Microbiome Transplantation (FMT) — capsules containing processed stool from healthy donors
- What this could lead to
- If successful, this could offer a new way to delay or prevent serious complications of advanced liver disease, potentially reducing the need for liver transplants.
- What could go wrong
- This is an early-phase trial with 190 participants, so results may not apply to all patients. FMT carries risks of infection or immune reactions, and the long-term effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DECOMPENSATED CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Corporació Sanitaria Universitaria Parc Taulí
RECRUITINGSabadell, Spain
Contact
-
Hospital Clínic de Barcelona
RECRUITINGBarcelona, Spain
Contact
Contact
-
Hospital General Universitario Gregorio Marañón
RECRUITINGMadrid, Spain
Contact
-
Hospital General Universitario Puerta de Hierro
RECRUITINGMadrid, Spain
Contact
-
Hospital Universitari Vall Hebron
RECRUITINGBarcelona, Spain
Contact
-
Hospital Universitario Marqués de Valdecilla
RECRUITINGSantander, Spain
Contact
-
Hospital Universitario Ramón y Cajal
RECRUITINGMadrid, Spain
Contact
-
Hospital de la Santa Creu i Sant Pau
RECRUITINGBarcelona, Spain
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can smarter antibiotic choices curb superbugs in liver disease?
- New study investigates hidden heart risk in liver patients
- Can the liver heal itself? new study tracks unexpected recovery in cirrhosis patients
- Heart drug may worsen advanced liver disease – major trial underway
- Smartwatch and app could keep liver patients out of hospital
- Cell injection aims to repair damaged livers in early trial